BioFlorida: Financing a Life Science Company (TUESDAY, August 28)

Financing A Life Science Company In Today’s Market

WHEN: Tuesday, August 28

TIME: 5:30 – 7:30 PM

WHERE: UM Life Science & Technology Park

1951 NW 7th Avenue

Miami, FL 33136

UM Life Science & Technology Park

Agenda

5:30 – 6:00 PM Registration & Networking

6:00 – 6:15 PM Welcome & Introductions

Michael Keller, Partner, Roetzel & Andress & Co-Chair, Miami-Broward Chapter, BioFlorida

6:15 – 7:15 PM Speakers

Dale Bergman, Partner, Roetzel & Andress “Financing Early Stage BioPharma Startups”

Greg Carney, COO, Nuovo Biologics

Jules A. Müsing, Chairman, Scientific Advisory Board, Noble Financial Capital Markets “Why not us? Why not me? An experienced large pharma dealmaker’s insights into why some companies and executives close deals and others do not.”

7:15 – 7:30 PM Closing Remarks & Additional Networking

Gina Alexis, President, The Alexis Group Consultants & Co-Chair, Miami-Broward Chapter, BioFlorida

Speaker Bios

Jules A. Müsing

Mr. Jules A. Müsing is a retired Senior Executive with more than 36 years experience in the pharmaceutical and biotechnology industry on a global basis. Mr. Müsing has been President of a U.S.-based Johnson & Johnson Company (Pitman-Moore, Inc.); Managing Director of Janssen Pharmaceutical (a J&J Company) in Portugal; Managing Director of Ortho Biotech (a J&J Biotechnology Company) in France; President of Ares Serono, Inc. in the U.S., and Executive Vice President with responsibility for Ares Serono Companies in North and Latin America. Mr. Müsing has been on the Board of Johnson & Johnson Companies in Germany, France, Italy and the UK, and has been a Member of the Management Board of Ortho Biotech, Inc. (a J&J Biotechnology Company) in the US. Early on in his career at Johnson & Johnson, Mr. Müsing was responsible for the Business Development activities of Janssen Pharmaceutical (a J&J Company) in South East Asia, and was Vice President Marketing International for the Janssen Pharmaceutical Group of Companies Worldwide, with responsibility for the launch and marketing of several multi-hundred million dollar pharmaceutical products in various therapeutic areas on a worldwide basis. Prior to his retirement from Johnson & Johnson in 2010, Mr. Müsing was responsible for the Licensing and Acquisition of Human Pharmaceutical and Biotechnology products for the Johnson & Johnson Pharmaceutical Group Worldwide. Jules Müsing is founder and CEO of Ambiorix Capital, LLC. He is on the Board of several companies and is Chairman of the Scientific Board of Advisors for Noble Financial Capital Markets, a full-service Investment Banking Company.

Dale Bergman

Mr. Bergman’s practice focuses on corporate, securities, business transactions and real estate matters. His wide array of business transactions have included commercial transactions, mergers and acquisitions, corporate restructurings, joint ventures, development and manufacturing agreements, strategic alliances, operating and shareholder’s agreements, and venture capital and private investments. He has negotiated technology licenses, bank, institutional and bond financings, aircraft purchases, leases and financings, and secured transactions. Mr. Bergman has represented a number of publicly and privately held companies engaged in the pharmaceutical and medical device fields including Andrx Corporation,Fuse Science, Inc., Non-Invasive Monitoring Systems, Inc. and Scion Cardio-Vascular, Inc. Dale received his A.B. from Columbia University and his J.D. from Harvard Law School.

About BioFlorida

BioFlorida is the voice of Florida’s bioscience industry representing more

than 3,000 companies and research organizations in the biotechnology,

pharmaceutical and medical device fields employing 61,000 Floridians.

BioFlorida’s member-driven initiatives provide a strong business climate for

production of quality, life-improving technologies and promote economic

benefits to the state.

Visit www.bioflorida.com for more information.

For Membership information or to join please visit www.bioflorida.com or call

Stacey Silver, VP of Member Relations at 561-653-3839. If you join within 7 days

of this program you will receive a 5% discount off your first year membership.

Driving Directions

The UM Life Science & Technology Park, Research & Development Building 1, is located on the Northeastern section of the Miami Health District at the intersection of NW 20th Street and NW 7th Avenue, Miami, FL 33136. Its central location makes it ideal for businesses, less than 10 minutes to both the business district of downtown Miami and the Miami International Airport.

From I-95, from points North:

Exit I-95 at SR 836 West, exit number 3-A. Exit SR 836 at NW 14th St. Head West to NW 9 Ave (Bob Hope Road). Turn right on 9th Ave North to NW 17th Street. Turn right on 17th St. East to NW 7th Ave. Turn left on NW 7th Ave. Head North on NW 7th Ave., entrance to park Leasing Office will be on the right after NW 17th St. directly off of 7th Avenue.

From I-95, from points South and East:

Exit I-95 at SR 836 West. Exit SR 836 at NW 12th Ave. and turn right onto NW 12th Ave. Turn right at NW 14th St. Head East to NW 7th Ave. Turn left at NW 7th Ave. Head North on NW 7th Ave. and entrance to park Leasing Office will be on the right after NW 17th St. directly off of 7th Avenue.

From SR 836 (Airport), and from points West:

Take SR 836 East and exit at NW 17th Ave., North. Take the Hospitals and Civic Center Exit, which is at the far right toll booths. Follow signs and turn right at the stop sign on NW 17th Ave. Head North and turn right at NW 14th St. Head East to NW 7th Ave. Turn left at NW 7th Ave. Head North on NW 7th Ave. and entrance to park Leasing Office will be on the right after NW 17th St. directly off of 7th Avenue.